Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.

This multicenter real-world study evaluated belumosudil (BEL), a selective ROCK2 inhibitor, in 46 heavily pretreated pat...

Continue ReadingReal-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

This publication reviews the advancements in frontline treatment for newly diagnosed, transplant-eligible multiple myelo...

Continue Reading35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.